Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platelet inhibition versus rivaroxaban after percutaneous closure of PFO or ASD
2021-005788-34Phase 2Active
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of rivaroxaban in patent foramen ovale (PFO) and atrial septal defect (ASD) (2 arms), sponsored by St. Antonius Ziekenhuis. Primary endpoint: Hemostatic endpoints. Started Mar 2022; status: active.
02
Drugs
rivaroxaban
03
Conditions
patent foramen ovale (PFO)atrial septal defect (ASD)
Beyond the preview
Go deeper on 2021-005788-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005788-34.